The use of PanDrugs to prioritize anticancer drug treatments in a case of T-ALL based on individual genomic data
[Background] Acute T-cell lymphoblastic leukaemia (T-ALL) is an aggressive disorder derived from immature thymocytes. The variability observed in clinical responses on this type of tumours to treatments, the high toxicity of current protocols and the poor prognosis of patients with relapse or refrac...
| Autores: | , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2019 |
| País: | España |
| Institución: | Consejo Superior de Investigaciones Científicas (CSIC) |
| Repositorio: | DIGITAL.CSIC. Repositorio Institucional del CSIC |
| OAI Identifier: | oai:digital.csic.es:10261/193534 |
| Acceso en línea: | http://hdl.handle.net/10261/193534 |
| Access Level: | acceso abierto |
| Palabra clave: | T-ALL Next-generation sequencing technologies PanDrugs Precision oncology Personalized precision medicine Translational bioinformatics Cancer genomics In silico prescription Targeted therapy Druggable genome |
| Sumario: | [Background] Acute T-cell lymphoblastic leukaemia (T-ALL) is an aggressive disorder derived from immature thymocytes. The variability observed in clinical responses on this type of tumours to treatments, the high toxicity of current protocols and the poor prognosis of patients with relapse or refractory make it urgent to find less toxic and more effective therapies in the context of a personalized medicine of precision. |
|---|